IN THE COURT OF APPEAL OF NEW ZEALAND
CA22/03
BETWEENPFIZER INC
Appellant
ANDCOMMISSIONER OF PATENTS
Respondent
Hearing:9 and 10 February 2004
Coram:Anderson P
Glazebrook J
Hammond J
William Young J
O'Regan JAppearances: A H Brown QC and G F Arthur for Appellant
B W F Brown QC and D A Laurenson for Respondent
Judgment:28 June 2004
JUDGMENTS OF THE COURT
Judgments
PARA NO
ANDERSON P [1]-[8]
Glazebrook, William Young and O’Regan JJ [9]-[94]
Hammond J [95]-[134]
ANDERSON P
[1] This Court held in Wellcome Foundation Ltd v Commissioner of Patents [1983] NZLR 385 that a patent may not be granted under the Patents Act 1953 for a method of treating disease or illness in human beings. That view was conventional. It conformed with English jurisprudence which had its roots in the Statute of Monopolies 1623 (21Jac 1,c3), s6 of which is imported by reference into the New Zealand statute.
[2] The Jacobean statute may have been more aptly named the Statute against Monopolies, for its elemental purpose was to proscribe the royal grant of monopolies; but consistent with an appreciation that it is in the public interest to encourage inventiveness and the dissemination of knowledge the statute accepted “any manner of new manufactures” provided “they be not contrary to the law, nor mischievous to the State, by raising prices of commodities at home, or hurt of trade, or generally inconvenient”. A monopoly could be granted by letters patent and grants of privilege for a term of up to 14 years “to the true and first inventor and inventors of such manufactures”.
[3] Over the past four centuries public interest has led the Courts to expand the concept of “manner of new manufactures” to connote almost any new discovery outside the ambit of the s6 proviso. The meaning of s6, and therefore the patentability of a discovery, is a matter of evolved judicial interpretation. The juridical basis for the exclusion of methods of medical treatment lies therefore not in a narrow reading of the ancient statute but in the historical and conceptual connotations of its judicial exposition. As the High Court of Australia explained in National Research Development Corporation v Commissioner of Patents (1959) 102 CLR 252 at 269:
The inquiry which the definition demands is an inquiry into the scope of the permissible subject matters of letters patent and grants of privilege … it is an inquiry not into the meaning of a word so much as into the breadth of the concept which the law has developed by its consideration of the text and purpose of the Statute of Monopolies.
[4] Although methods of medical treatment were considered incapable of being patented, the use of a known compound for a recognised inventive purpose evolved into what is known as a Swiss claim. The purpose of such claims is to accord, for socially utile reasons, a monopoly which permits the economic exploitation of an intellectual discovery without constraining its potential for use once paid for. The device rewards…
Keep reading for free
Create a free CaseChat account to read Pfizer Inc v Commissioner of Patents and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2004] NZCA 104
- Decision Date
CaseChat Overview and Summary
Orders
Orders of the court
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi